XOMA Co. (NASDAQ:XOMA) Receives Average Rating of “Hold” from Analysts

XOMA Co. (NASDAQ:XOMA – Get Rating) has received an average rating of “Hold” from the six brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $49.00.

XOMA has been the topic of several recent analyst reports. Zacks Investment Research cut XOMA from a “hold” rating to a “strong sell” rating in a research note on Saturday, January 8th. TheStreet raised XOMA from a “c-” rating to a “b-” rating in a report on Friday, April 1st. Finally, StockNews.com lowered XOMA from a “buy” rating to a “hold” rating in a report on Monday, April 4th.

In other news, CEO James R. Neal sold 1,111 shares of the business’s stock in a transaction on Wednesday, March 23rd. The shares were sold at an average price of $30.02, for a total transaction of $33,352.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO James R. Neal sold 50,000 shares of the business’s stock in a transaction on Monday, March 21st. The shares were sold at an average price of $29.00, for a total transaction of $1,450,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 53,450 shares of company stock valued at $1,553,569. 9.90% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Geneos Wealth Management Inc. acquired a new position in shares of XOMA during the third quarter valued at $25,000. Citigroup Inc. boosted its holdings in shares of XOMA by 118.0% during the fourth quarter. Citigroup Inc. now owns 1,528 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 827 shares during the period. BNP Paribas Arbitrage SA boosted its holdings in shares of XOMA by 138.5% during the third quarter. BNP Paribas Arbitrage SA now owns 1,436 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 834 shares during the period. Barclays PLC boosted its holdings in shares of XOMA by 222.0% during the third quarter. Barclays PLC now owns 2,463 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 1,698 shares during the period. Finally, Morgan Stanley boosted its holdings in shares of XOMA by 181.6% during the second quarter. Morgan Stanley now owns 2,630 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 1,696 shares during the period. 56.14% of the stock is owned by institutional investors.

Shares of NASDAQ:XOMA traded down $1.36 during trading on Tuesday, hitting $24.18. The company’s stock had a trading volume of 43,624 shares, compared to its average volume of 28,493. XOMA has a fifty-two week low of $19.08 and a fifty-two week high of $39.49. The stock’s 50-day moving average price is $24.15 and its two-hundred day moving average price is $23.40. The company has a market capitalization of $275.56 million, a PE ratio of 161.21 and a beta of 0.89.

XOMA (NASDAQ:XOMA – Get Rating) last released its quarterly earnings results on Tuesday, March 8th. The biotechnology company reported $1.67 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.27 by ($0.60). XOMA had a return on equity of 4.93% and a net margin of 14.57%. The business had revenue of $35.94 million during the quarter, compared to analyst estimates of $34.84 million.

About XOMA (Get Rating)

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.

Featured Articles